Cilamox
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. CILAMOX amoxicillin Consumer Medicine Information What is in this leaflet This leaflet […]
Read moreHome » Medications »
FDA Approves Lupkynis
FDA Approves Lupkynis (voclosporin) for Adult Patients with Active Lupus Nephritis VICTORIA, British Columbia & ROCKVILLE, Md.– January 22, 2021 — Aurinia Pharmaceuticals Inc. today […]
Read moreDarzalex Faspro (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of […]
Read moreLilly’s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19
INDIANAPOLIS, Nov. 9, 2020 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) today granted Emergency Use Authorization (EUA) for Eli Lilly and Company’s (NYSE: LLY) investigational neutralizing […]
Read moreVerrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts (CARE-1)
WEST CHESTER, Pa., November 10, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring […]
Read moreGeneTx and Ultragenyx Announce Positive Interim Phase 1/2 Data on Investigational GTX-102 Demonstrating Improvement in Patients with Angelman Syndrome
SARASOTA, Fla. and NOVATO, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) — GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development […]
Read moreCureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate CVnCoV
TÜBINGEN, Germany / BOSTON, USA – October 23, 2020 — CureVac NV (Nasdaq: CVAC), a biopharmaceutical company developing a new class of drugs based on […]
Read moreMirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn’s Disease in 52-Week Phase 2 Trial
INDIANAPOLIS, Oct. 12, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) announced today new efficacy and safety data from the Phase 2 SERENITY study evaluating mirikizumab in patients […]
Read moreFDA Approves Bausch + Lomb Alaway Preservative Free (Ketotifen Fumarate) Ophthalmic Solution, 0.035%
LAVAL, QC and DEER PARK, Ill., Sept. 25, 2020 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), Bausch + Lomb, a leading global eye health […]
Read moreJohnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., September 23, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) […]
Read more